Associate Professor, Medicine, University of Maryland School of Medicine
Oncology
Dr. Ronald B. Gartenhaus, MD
|
|
Give Review
Ronald Gartenhaus works in the field of Oncology. Ronald Gartenhaus has written publications. He has 74 publications published with PubMed. The lastest publication is: 'A novel candidate oncogene, MCT-1, is involved in cell cycle progression.' Doctor Ronald B. Gartenhaus, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models.
- Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
- Vγ2Vδ2 T cell Costimulation Increases NK cell Killing of Monocyte-derived Dendritic Cells.
- Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell Lymphoma development.
- Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of Malignant B-cell lymphomas.
- Epigenetic approaches for chemosensitization of refractory diffuse large B-cell Lymphomas.
- Role of microRNA deregulation in the pathogenesis of diffuse large B-cell Lymphoma (DLBCL).
- c-Myc and E2F1 drive PBK/TOPK expression in high-grade Malignant lymphomas.
- The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic Malignancies.
- Promising personalized therapeutic options for diffuse large B-cell Lymphoma subtypes with oncogene addictions.
- Interleukin-7 inhibits tumor-induced CD27-CD28- suppressor T cells: implications for Cancer immunotherapy.
- The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell Lymphoma.
- ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes.
- AMPK signaling: a targetable tumor suppressor pathway?
- Targeting the translational machinery as a novel treatment strategy for hematologic Malignancies.
- Survival prediction and gene identification with penalized global AUC maximization.
- Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell Lymphoma.
- Alcohol consumption and decreased risk of non-Hodgkin Lymphoma: role of mTOR dysfunction.
- Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach.
- The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation.
- MCT-1 protein interacts with the cap complex and modulates messenger RNA translational profiles.
- MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.
- Oncogenes as molecular targets in Lymphoma.
- Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple Myeloma cells.
- Bcl-2 regulatory pathway is functional in chronic lymphocytic Leukemia.
- Treatment of T-cell non-Hodgkin's Lymphoma.
- Imexon-induced apoptosis in multiple Myeloma tumor cells is caspase-8 dependent.
- Clinical screening of gene rearrangements in childhood Leukemia by using a multiplex polymerase chain reaction-microarray approach.
- Identification and characterization of a novel enhancer for the human MCT-1 oncogene promoter.
- Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid Malignancies.
- Molecular etiology of mature T-cell non-Hodgkin's Lymphomas.
- Chronic lymphocytic Leukemia manifesting in the paranasal sinuses.
- Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox State.
- MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.
- Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell Lymphoma.
- Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell Lymphoma.
- Kernel based methods for accelerated failure time model with ultra-high dimensional data.
- Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in proState cancer.
- Transcriptional profiling of chronic lymphocytic Leukemia: is there still more to learn?
- Gene and pathway identification with Lp penalized Bayesian logistic regression.
- Post-transcriptional control of the MCT-1-associated protein DENR/DRP by RNA-binding protein AUF1.
- MCT-1 oncogene downregulates p53 and destabilizes genome structure in the response to DNA double-strand damage.
- Characterization of the MCT-1 pseudogene: identification and implication of its location in a highly amplified region of chromosome 20.
- Expression of DNA mismatch repair proteins in transformed non-Hodgkin''s Lymphoma: relationship to smoking.
- Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic Leukemia: dawn of a new era.
- The potential of arsenic trioxide in the treatment of Malignant disease: past, present, and future.
- MSRE-PCR for analysis of gene-specific DNA methylation.
- The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells.
- DAB389IL2 (ONTAK) fusion protein therapy of Chronic lymphocytic leukaemia.
- A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic Leukemia.
- Expression and stabilization of the MCT-1 protein by DNA damaging agents.
- HTLV-I associated Leukemia/lymphoma: epidemiology, biology, and treatment.
- Retinoic acid modulates a bimodal effect on cell cycle progression in human adult T-cell Leukemia cells.
- Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1.
- A novel candidate oncogene, MCT-1, is involved in cell cycle progression.
- Microsatellite instability in hematologic Malignancies.
- Allelic loss determination in chronic lymphocytic Leukemia by immunomagnetic bead sorting and microsatellite marker analysis.
- The induction of p53 and WAF1/CIP1 in chronic lymphocytic Leukemia cells treated with 2-chlorodeoxyadenosine.
- Differentiating agents do not induce a true hairy cell phenotype in B-CLL cells in vitro.
- Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T lymphocytes.
- Induction of the WAF1/CIP1 protein and apoptosis in human T-cell Leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independe...
- Mutator phenotype in a subset of chronic lymphocytic Leukemia.
- Relative activities of HIV-1-IIIB and HIV-1BaL LTR and tat in primary monocytes and lymphocytes.
- The promoter of human T-cell Leukemia virus type-I is repressed by the immediate-early gene region of human cytomegalovirus in primary blood lymphocytes.
- cDNA sequencing confirms HTLV-I expression in adult T-cell Leukemia/lymphoma and different sequence variations in vivo and in vitro.
- Expression of alternatively spliced human T-lymphotropic virus type I pX mRNA in infected cell lines and in primary uncultured cells from patients with adult T-cell le...
- Human T-cell lymphotropic-I-associated Leukemia/lymphoma.
- Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage.
- Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a Cancer stem cell targeting mechanism.
- Targeted suppression of MCT-1 attenuates the Malignant phenotype through a translational mechanism.
- Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype.
- PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
- Ribosomal protein S6 is highly expressed in non-Hodgkin Lymphoma and associates with mRNA containing a 5'' terminal oligopyrimidine tract.
Schools
University of The Northeast School of Medicine
University HospSUNY
MD Anderson Hospital
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas MD Anderson Cancer Center -
SUNY Stony Brook University Hospital & Medical Center -
Universidad del Noreste
Hospital
-
University of Maryland Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1376583864 |
| Last Name Of The Provider | GARTENHAUS |
| First Name Of The Provider | RONALD |
| View All |
Similar Doctors
|
|
Dr. Stephen H. Glasser, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mei Tang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ting Bao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arif Hussain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul C. Celano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saranya A. Chumsri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward A. Sausville, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Dan L. Longo, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Christine L. Hann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth J. Pienta, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Paula M. Rosenblatt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol A. Huff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rosalyn A. Juergens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua E. Lubek, MD
This Doctor is OpenDoctor Recommended.
|